Ardelyx, Inc. (ARDX)
NASDAQ: ARDX · Real-Time Price · USD
5.73
-1.01 (-14.99%)
At close: Feb 20, 2026, 4:00 PM EST
5.79
+0.06 (1.03%)
After-hours: Feb 20, 2026, 7:59 PM EST
Ardelyx Employees
Ardelyx had 395 employees as of December 31, 2024. The number of employees increased by 128 or 47.94% compared to the previous year.
Employees
395
Change (1Y)
128
Growth (1Y)
47.94%
Revenue / Employee
$1,031,190
Profits / Employee
-$155,947
Market Cap
1.41B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 395 | 128 | 47.94% |
| Dec 31, 2023 | 267 | 134 | 100.75% |
| Dec 31, 2022 | 133 | 47 | 54.65% |
| Dec 31, 2021 | 86 | -43 | -33.33% |
| Dec 31, 2020 | 129 | 41 | 46.59% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Immatics | 645 |
| Intellia Therapeutics | 403 |
| uniQure | 209 |
| Capricor Therapeutics | 160 |
| Zenas BioPharma | 130 |
| MoonLake Immunotherapeutics | 100 |
| Savara | 59 |
| AtaiBeckley | 54 |
ARDX News
- 1 hour ago - Why Ardelyx's Offensive Strategy Doesn't Move The Needle - Seeking Alpha
- 18 hours ago - Ardelyx: Strong IBSRELA Growth, But Heavy Operational Spend Clouds Profitability - Seeking Alpha
- 22 hours ago - Ardelyx Lead Drug Growth Fails To Lift Sentiment, Stock Drops - Benzinga
- 1 day ago - Ardelyx, Inc. (ARDX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 15 days ago - Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026 - GlobeNewsWire
- 17 days ago - Ardelyx Receives New Patent for Tenapanor - GlobeNewsWire
- 23 days ago - First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA - GlobeNewsWire